Mpox Airborne Transmission: A Systematic Review.

Rev Med VirolSep 1, 2026
Clinical ResearchInfectious DiseasesOpen access

Lucas Ferreira Theotonio Dos Santos, Leonardo Javier Arcuri, Viviane Aparecida R Sant'Anna et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the risk of airborne transmission of mpox by analyzing four environmental studies published between 2022 and 2023. While MPXV DNA was detected in air samples, none of the studies showed consistent viral viability in aerosols or droplets, indicating no clear risk of airborne transmission.

Key findings

  • MPXV DNA was detected in air samples with cycle threshold (Ct) values ranging from <30 to <45.
  • None of the studies demonstrated consistent viral viability in aerosols or droplets.
  • The evidence does not support a clear risk of airborne infection.

Why it matters

Understanding the transmission routes of mpox is crucial for public health strategies, especially in managing outbreaks in nonendemic regions. This review highlights the limited evidence for airborne transmission, guiding infection control measures.

Source

PubMed · PMID 42576377Free full text on PubMed Central

Published in Rev Med Virol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.